共 25 条
Patient-specific evolution of renal function in chronic heart failure patients dynamically predicts clinical outcome in the Bio-SHiFT study
被引:42
作者:
Brankovic, Milos
[1
,2
]
Akkerhuis, K. Martijn
[1
]
van Boven, Nick
[1
]
Anroedh, Sharda
[1
]
Constantinescu, Alina
[1
]
Caliskan, Kadir
[1
]
Manintveld, Olivier
[1
]
Cornel, Jan Hein
[3
]
Baart, Sara
[1
]
Rizopoulos, Dimitris
[4
]
Hillege, Hans
[5
]
Boersma, Eric
[1
]
Umans, Victor
[3
]
Kardys, Isabella
[1
]
机构:
[1] Erasmus MC, Dept Cardiol, Rotterdam, Netherlands
[2] Univ Belgrade, Sch Med, Belgrade, Serbia
[3] Noordwest Ziekenhuisgrp, Dept Cardiol, Alkmaar, Netherlands
[4] Erasmus MC, Dept Biostat, Rotterdam, Netherlands
[5] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands
关键词:
dynamic prediction;
heart failure;
individual risk;
renal dysfunction;
temporal evolution;
tubular markers;
EUROPEAN-SOCIETY;
EJECTION FRACTION;
ASSOCIATION HFA;
TUBULAR DAMAGE;
TASK-FORCE;
BIOMARKERS;
DIAGNOSIS;
COLLABORATION;
GUIDELINES;
SURVIVAL;
D O I:
10.1016/j.kint.2017.09.013
中图分类号:
R5 [内科学];
R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号:
100201 [内科学];
100221 [泌尿外科学];
摘要:
Renal dysfunction is an important component of chronic heart failure (CHF), but its single assessment does not sufficiently reflect clinically silent progression of CHF prior to adverse clinical outcome. Therefore, we aimed to investigate temporal evolutions of glomerular and tubular markers in 263 stable patients with CHF, and to determine if their patient-specific evolutions during this clinically silent period can dynamically predict clinical outcome. We determined the risk of clinical outcome (composite endpoint of Heart Failure hospitalization, cardiac death, Left Ventricular Assist Device placement, and heart transplantation) in relation to marker levels, slopes and areas under their trajectories. In each patient, the trajectories were estimated using repeatedly measured glomerular markers: creatinine/estimated glomerular filtration rate (eGFR), cystatin C (CysC), and tubular markers: urinary N-acetyl-beta-D-glucosaminidase (NAG) and kidney injury molecule (KIM)-1, plasma and urinary neutrophil gelatinase-associated lipocalin (NGAL). During 2.2 years of follow-up, we collected on average 8 urine and 9 plasma samples per patient. All glomerular markers predicted the endpoint (univariable hazard ratio [95% confidence interval] per 20% increase: creatinine: 1.18 [1.07-1.31], CysC: 2.41[ 1.81-3.41], and per 20% eGFR decrease: 1.13[1.05-1.23]). Tubular markers, NAG, and KIM-1 also predicted the endpoint (NAG: 1.06[1.01-1.11] and KIM-1: 1.08[1.04-1.11]). Larger slopes were the strongest predictors (creatinine: 1.57[1.39-1.84], CysC: 1.76 [1.52-2.09], eGFR: 1.59[1.37-1.90], NAG: 1.26[1.11-1.44], and KIM-1: 1.64[1.38-2.05]). Associations persisted after multivariable adjustment for clinical characteristics. Thus, during clinically silent progression of CHF, glomerular and tubular functions deteriorate, but not simultaneously. Hence, patient-specific evolutions of these renal markers dynamically predict clinical outcome in patients with CHF.
引用
收藏
页码:952 / 960
页数:9
相关论文

